stoxline Quote Chart Rank Option Currency Glossary
  
Denali Therapeutics Inc. (DNLI)
20.52  -0.25 (-1.2%)    03-28 16:00
Open: 20.86
High: 21.04
Volume: 957,299
  
Pre. Close: 20.77
Low: 20.12
Market Cap: 2,856(M)
Technical analysis
2024-03-28 4:50:52 PM
Short term     
Mid term     
Targets 6-month :  27.47 1-year :  32.08
Resists First :  23.52 Second :  27.47
Pivot price 20.51
Supports First :  19.16 Second :  16.46
MAs MA(5) :  20.13 MA(20) :  20.53
MA(100) :  19.16 MA(250) :  23.03
MACD MACD :  0.3 Signal :  0.4
%K %D K(14,3) :  43.7 D(3) :  33.3
RSI RSI(14): 53.6
52-week High :  33.31 Low :  15.44
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ DNLI ] has closed below upper band by 49.9%. Bollinger Bands are 49.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 21.05 - 21.16 21.16 - 21.24
Low: 19.88 - 19.99 19.99 - 20.07
Close: 20.34 - 20.53 20.53 - 20.67
Company Description

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Headline News

Thu, 28 Mar 2024
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report? - Yahoo Finance

Sun, 24 Mar 2024
Denali Therapeutics (NASDAQ:DNLI) Shares Down 5.8% - Defense World

Fri, 22 Mar 2024
Denali Therapeutics files to sell 29.29M shares of common stock for holders - Seeking Alpha

Thu, 21 Mar 2024
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25% - Simply Wall St

Wed, 20 Mar 2024
Denali Therapeutics (NASDAQ:DNLI investor three-year losses grow to 67% as the stock sheds US$223m this past week - Simply Wall St

Tue, 19 Mar 2024
Further weakness as Denali Therapeutics (NASDAQ:DNLI) drops 7.4% this week, taking three-year losses to 67% - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 139 (M)
Shares Float 120 (M)
Held by Insiders 13.8 (%)
Held by Institutions 79.4 (%)
Shares Short 8,870 (K)
Shares Short P.Month 9,840 (K)
Stock Financials
EPS -1.06
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.44
Profit Margin -44 %
Operating Margin -59.6 %
Return on Assets (ttm) -9.4 %
Return on Equity (ttm) -14.1 %
Qtrly Rev. Growth -100 %
Gross Profit (p.s.) 0
Sales Per Share 2.37
EBITDA (p.s.) -1.36
Qtrly Earnings Growth 0 %
Operating Cash Flow -358 (M)
Levered Free Cash Flow -298 (M)
Stock Valuations
PE Ratio -19.36
PEG Ratio 0
Price to Book value 2.75
Price to Sales 8.63
Price to Cash Flow -7.98
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android